1	No evidence for intervention-associated DNA methylation changes in monocytes of
2	patients with posttraumatic stress disorder or anorexia nervosa
3	
4	Elisabeth Hummel ^{1¶} , Magdeldin Elgizouli ^{2¶} , Jasmin Beygo ² , Johanna Giuranna ³ , Maurizio
5	Sicorello ⁴ , Elsa Leitão ² , Christopher Schröder ^{2,5} , Michael Zeschnigk ² , Svenja Müller ¹ , Dana
6	Öztürk ³ , Manuel Föcker ⁶ , Stephan Herpertz ⁷ , Johannes Hebebrand ³ , Dirk Moser ¹ , Henrik Kessler ⁷ ,
7	Bernhard Horsthemke ^{2*} , Anke Hinney ^{3*} , Robert Kumsta ^{1*}
8	
9	
10	¹ Department of Genetic Psychology, Faculty of Psychology, Ruhr University Bochum, Germany
11	² Institute of Human Genetics, University of Duisburg-Essen, University Hospital Essen, Essen, Germany
12	³ Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital
13	Essen, University of Duisburg-Essen, Germany
14	⁴ Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health, Medical
15	Faculty Mannheim, Heidelberg University, Germany
16	⁵ Genome Informatics, Institute of Human Genetics, University of Duisburg-Essen, University Hospital Essen,
17	Essen, Germany
18	⁶ Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital
19	Münster, Germany
20	⁷ Department of Psychosomatic Medicine and Psychotherapy, LWL-University Hospital, Ruhr University Bo-
21	chum, Germany
22	
23	[*] Correspondence: bernhard horsthemke@uni-due de anke hinnev@uni-due de robert kumsta@rub de
23 24	
2 4 25	
25 26	[¶] These authors contributed equally
20 27	These autions contributed equality
<i>∠</i> /	

28 Abstract

29 DNA methylation patterns can be responsive to environmental influences. This observation has 30 sparked interest in the potential for psychological interventions to influence epigenetic processes. 31 Recent studies have observed correlations between DNA methylation changes and therapy out-32 come. However, most did not control for changes in cell composition from pre- to post-therapy. 33 This study had two aims: first, we sought to replicate therapy-associated changes in DNA methyla-34 tion of commonly assessed candidate genes in isolated monocytes from 60 female patients with 35 post-traumatic stress disorder (PTSD) using targeted deep bisulfite sequencing (DBS). Our second, exploratory goal was to identify novel genomic regions with substantial pre-to-post interven-36 37 tion DNA methylation changes by performing whole-genome bisulfite sequencing (WGBS) in two 38 patients with PTSD and three patients with anorexia nervosa (AN) before and after intervention. 39 Equivalence testing and Bayesian analyses provided evidence against physiologically meaningful 40 intervention associated DNA methylation changes in monocytes of PTSD patients in commonly 41 investigated target genes (NR3C1, FKBP5, SLC6A4, OXTR). Furthermore, WGBS yielded only a 42 limited set of candidate regions with suggestive evidence of differential methylation pre- to post-43 therapy. These differential methylation patterns did not prove replicable when investigated in the 44 entire cohort. We conclude that there is no evidence for major, recurrent intervention-associated 45 DNA methylation changes in the investigated genes in monocytes of patients with either PTSD or 46 AN.

48 Author Summary

49 Many mental health problems have developmental origin, and epigenetic mechanisms have 50 been proposed to explain the link between stressful or adverse experiences and subsequent 51 health outcomes. More recently, studies have begun to examine whether psychological ther-52 apies might influence or even reverse supposedly acquired DNA methylation marks. Correla-53 tions between response to therapy and DNA methylation changes in peripheral tissue have 54 been reported; however, these results might be confounded by differences in cell composi-55 tion between time points and not reflect true DNA methylation changes. Here, we attempted 56 to replicate previous reported results in a homogenous cell population (monocytes) and fur-57 ther to identify novel intervention-responsive regions in the whole genome in patients with 58 post-traumatic stress disorder (PTSD) and anorexia nervosa (AN). Our results showed that the improvement in symptomatology in PTSD and AN patients was 59 60 not reflected in changes in DNA methylation in monocytes, neither in the previously studied

candidate genes nor in the regions identified by whole-genome bisulfite sequencing. This
 study provides evidence against DNA methylation changes in peripheral tissue following
 therapy, and we suggest that previous findings are most likely explained by differences in cell
 composition.

66 Introduction

67 The concept of an environmentally regulated epigenome has attracted considerable attention in 68 the mental health field [1, 2]. Many psychopathologies have developmental origins, and epigenetic 69 processes have been suggested as targets for the effects of psychosocial adversity particularly in 70 early life. The epigenome is an umbrella term for a range of mechanisms involved in gene regula-71 tion, including DNA methylation, histone modifications and regulation through non-coding RNA 72 molecules [3]. Epigenetic processes are essential for normal cellular differentiation and develop-73 ment. Perturbations in these processes have been linked to different pathologies [4], including 74 mental disorders [5]. Both animal models and human studies have pointed to persistent epigenetic 75 changes in response to various stimuli. These changes, it has been argued, might reflect or medi-76 ate the long-term effects of early risk exposure such as prenatal malnutrition on metabolic out-77 comes [6]. Another often quoted example of epigenetic mediation is the programming of the neu-78 roendocrine stress response by the degree of maternal care in rodents [7].

DNA methylation, which involves methylation of cytosines predominantly in cytosine-guanine (CpG) dinucleotides, has long been thought to represent an early-established and rather stable epigenetic marker. A number of recent studies have shown, however, that DNA methylation patterns are more dynamic than previously thought, and can change in response to internal signals or environmental influences [8-12]. These observations have sparked interest in the potential for psychological and nutritional interventions (e.g. in Anorexia Nervosa) to influence these biological processes.

86 Several studies have been published that assessed DNA methylation before and after therapeutic 87 intervention [see 13 for review]. Most followed a candidate-gene approach and investigated genes 88 involved in stress regulation, such as the Glucocorticoid Receptor (NR3C1) or FKBP Prolyl 89 *Isomerase 5 (FKBP5)* [14-16], or genes commonly investigated in psychiatric genetics studies, 90 such as the Serotonin Transporter (SLC6A4; [17]), Monoamine Oxidase A (MAOA; [18]), and the 91 Brain Derived Neurotrophic Factor (BDNF; [19]). The studies conducted so far are very heteroge-92 neous in terms of investigated disorders (post-traumatic stress disorder, PTSD; anorexia nervosa, 93 AN; anxiety disorders, borderline personality disorder), analyzed tissue (buccal cells, whole blood,

94 peripheral blood mononuclear cells (PBMCs), as well as type of intervention and methodology for 95 exploring DNA methylation. A common feature of all investigations is the observation that therapy 96 responders and non-responders showed differential DNA methylation patterns pre- to post-97 intervention. For instance, in combat veterans with PTSD, DNA methylation levels of FKBP5 in 98 PBMC decreased in responders but increased in non-responders comparing pre- to post-therapy 99 measurements [16]. The first epigenome-wide investigation of intervention-associated DNA meth-100 ylation changes in PTSD further supported this notion. Successful psychotherapeutic treatment of 101 PTSD was associated with increases in DNA methylation of the Zinc Finger Protein 57 gene 102 (ZFP57) in whole blood, whereas DNA methylation in this region decreased during the develop-103 ment of PTSD, and also decreased in patients who did not respond to therapy [20]. A similar pic-104 ture emerged from an epigenome-wide study of AN. Here, longer duration of illness was associat-105 ed with lower DNA methylation levels in whole blood, whereas DNA methylation increased at the 106 same positions with a concomitant increase in body mass index (BMI) across therapy [21].

107 Taken together, DNA methylation changes have thus been suggested as a marker or epigenetic 108 correlate of therapy outcome. Caution is needed in the interpretation of these findings though. With 109 exception of the two epigenome-wide association studies, only a limited number of CpGs were 110 investigated, the observed changes were small, and the applied methods mostly had insufficient 111 sensitivity to reliably assess such small DNA methylation differences. Furthermore, it is unclear 112 whether differences in DNA methylation, as observed after the intervention, do not rather reflect 113 changes in the cellular composition of the investigated tissue. DNA methylation patterns are highly 114 cell type-specific, and each cell type within a tissue contributes to DNA methylation variation [22]. 115 Given that the cell composition of the circulating leukocyte pool is dynamic and influenced by vari-116 ous external factors, including infections, menstrual cycle [23] or stress exposure [24], DNA meth-117 vlation changes in blood collected at different time points from the same individual might primarily 118 reflect differences in cell composition [25], unrelated to the effect of intervention.

To address these limitations, we set out to investigate intervention-associated changes in DNA methylation in a homogenous cell population (CD14⁺ monocytes), in a female-only PTSD patients cohort. Monocytes were chosen as previous studies have shown that among the heterogeneous

122 leukocyte population, monocytes were the most sensitive subtype for traumatic experiences and

123 variation of psychosocial conditions [26].

124 The two goals of this study were, first, to replicate findings from previous reported intervention-125 associated candidate genes (NR3C1, FKBP5, SLC6A4, Oxytocin Receptor (OXTR) in a female-126 only PTSD cohort, and, second to identify new differentially methylated regions (DMRs) by per-127 forming an exploratory whole-genome bisulfite sequencing (WGBS). For the exploratory WGBS we 128 not only analyzed a sub-sample of the PTSD cohort but also examined a second independent fe-129 male AN cohort. AN has a metabolic component and therefore we expected to find more DMRs. 130 DNA methylation of commonly assessed candidate genes and promising targets from WGBS were 131 analyzed using targeted deep bisulfite sequencing (DBS). Our approach thus addressed essential 132 confounders, namely sex, cell heterogeneity, genetic variation, coverage of the genome and cov-133 erage of CpGs within candidate genes.

134

135 **Results**

136 Study 1 - Targeted analysis of previously investigated candidate genes

To address our first goal of replicating intervention-associated DNA methylation changes of previously assessed candidate genes, we investigated sixty female PTSD patients. Patients with PTSD had a clinically relevant reduction in PTSD symptoms, with a mean reduction of 15.6 \pm 14.6 (SD) on the PTSD-Check List [PCL-5; 27]. Thirty-six patients were classified as responder according to PCL-5 (drop by 10 points from pre- to post-treatment). The responders showed a mean difference between post- and pre-treatment in PCL-5 of -24.1 \pm 10.3, while the non-responders (n=21, 35%) showed a mean difference of -1.0 \pm 7.8 (PCL-5 data was missing for three patients).

DBS was performed for four candidate genes for which psychotherapy effects on DNA methylation change have been previously reported: *NR3C1*, *FKBP5*, *SLC6A4* and *OXTR* (see S1 Fig for exact chromosomal locations). Linear regression analysis showed no significant association between pre-treatment mean DNA methylation of DBS targets and the severity of baseline PTSD symptoms (S3 Table). Likewise there were no statistically significant differences in mean DNA methylation

149 between pre- and post-intervention for all investigated targets, even without correction for multiple 150 comparisons (all p > .05; Table 1). Intervention-associated changes in DNA Methylation of single 151 CpGs did not survive correction for multiple testing (S4 Table). Bayes factors favored the null hy-152 pothesis of no DNA methylation change for NR3C1 and FKBP5. Furthermore, DNA methylation 153 change was not conditional on therapy response (all p > 0.16; Table 1), with all Bayes factors larg-154 er than one and Bayes factors for SLC6A4 and FKBP5 above the threshold of three. Moreover, we 155 observed no statistically significant correlation between symptom changes and DNA methylation 156 changes (all p > 0.15; Table 2 and S2 Fig, upper row), with all Bayes factors larger than one and 157 Bayes factors for SLC6A4 and FKBP5 above three. Distributions of DNA methylation changes are 158 shown in Fig 1, upper row by responder status. The largest mean differences between time points 159 was found for OXTR (-0.26% \pm 1.21%), and the smallest was -0.019% \pm 0.19% for NR3C1. Mean 160 DNA methylation levels pre- and post-intervention averaged across the analyzed genomic regions 161 are shown in S3 Fig.

162 Complementary to the Bayes factor approach, equivalence test help infer whether true population 163 effect sizes are smaller than a pre-defined smallest effect size of interest. Effect sized for all candi-164 date genes were significantly smaller than 1% DNA methylation change, even in the therapy-165 responder group and after Bonferroni correction (all $p_{corrected} < .001$). The 95% confidence intervals 166 of difference scores in the responder group did not include methylation changes larger than 167 $\approx |0.5\%|$: $\Delta_{FKBP5} = 0.06\%$ [-0.28, 0.40], $\Delta_{SLC6A4} = -0.11\%$ [-0.33, 0.11], $\Delta_{OXTR} = -0.16\%$ [-0.52, 0.21], 168 $\Delta_{NR3C1} = 0.00\%$ [-0.06, 0.07].

We conclude that true effect sizes of all classic candidate genes are smaller than 1% DNA methyl-ation change.

171

172 Study 2 - Explorative whole-genome bisulfite sequencing

In addition to our goal of conceptually replicating previously reported results in candidate genes, we aimed to explore whether we could identify genomic regions with large pre-post intervention changes in DNA methylation in a limited sample, which could then be validated in the larger sample. Besides the PTSD patients, we included AN patients for explorative WGBS. Due to the strong

metabolic component during AN therapy, we expected a higher number of DMRs in the AN patients. Following recommendations by Ziller et al. [28], we sequenced at least two biological replicates at >5x coverage. Pre- and post-intervention monocyte DNA from two patients with PTSD and additionally from three AN patients was subjected to WGBS. The patients for the WGBS were selected based on their responsiveness to the therapy, absence of co-morbidity, and non-smoking status.

There was a slight difference in the genome-wide mean methylation levels between the PTSD and AN samples (0.72 vs. 0.75; Mann-Whitney U test; S5 Table). DNA methylation did not differ between pre- and post-intervention samples of the same individuals (p-value = 1; Wilcoxon signed rank test).

A principal component analysis (PCA) of the PTSD and AN methylomes did not group samples according to pre- or post-intervention state (S4 Fig). The same was observed in a cluster analysis of the 1,000 most variable CpGs for the PTSD and AN datasets, in which separate branches are observed for each individual (Fig 2). We observed large differences between individuals, most likely reflecting the different genetic backgrounds, but no recurrent differences between the pre- and post-intervention states.

To identify DMRs between pre- and post-treatment samples from each cohort, we used two different bioinformatic tools (camel and metilene; [29, 30]). Owing to lower coverage in the PTSD samples compared to the AN samples, we set the threshold to a minimum coverage of five reads and ten reads, respectively. Defining a camel DMR as a region with at least four CpGs and a minimum methylation difference of 0.3, we detected 33 DMRs in the PTSD patients (S6 Table). Using a filter of q < 0.05 for metilene DMRs, we detected four DMRs (S7 Table).

Using the same DMR filters, camel identified no DMRs in the AN data set, indicating that there are no major recurrent methylation changes. Since the samples of this cohort were sequenced at a higher depth, we decided to lower the minimum methylation difference between groups to 0.2 while at the same time increasing stringency by setting the minimum number of CpGs to 10. Using these filters, we identified 35 DMRs with camel (S8 Table). At q<0.05, metilene reported 10 DMRs, with seven DMRs being detected by both tools (S9 Table). There is one DMR common to the PTSD

and AN datasets, which overlaps the binding sites for CTCF and other transcription factors within intron 1 of *EXD3*, a gene encoding an exoribonuclease required for 3'-end trimming of AGO1bound miRNAs.

Validation of WGBS-nominated targets in the PTSD sample. DNA methylation pattern of four targets that emerged as potentially responsive to intervention from WGBS data were validated in the entire sample (n=60) using DBS. The following gene regions were analyzed: DMR-4 within *Adenosine A1 Receptor (ADORA1),* DMR-21 within *Tetraspanin 9 (TSPAN9),* DMR-10 within *Ribosomal Protein S6 Kinase A2 (RPS6KA2),* and intergenic DMR-1 (S6 Table). Chromosomal locations of the targets are shown in S1 Fig.

214 The effect sizes of ADORA1, RPS6KA2, and DMR-1 were all significantly smaller than 5% DNA 215 methylation change in both the whole cohort and the responder cohort (all $p_{corrected} < .001$). The 216 effect of TSPAN9 was only significantly different from 5% in the whole cohort on an uncorrected 217 p = .043, which did not survive Bonferroni correction. There were no statistically significant differ-218 ences in DNA methylation between pre- and post-intervention for the WGBS-nominated targets. 219 However, the possibility of a true effect size within the range of 5% DNA methylation difference at 220 the TSPAN9 between pre- and post-intervention samples cannot be ruled out. Bayes factors fa-221 vored the null hypothesis of no methylation change for RPS6KA2 and DMR-1. Similar to candidate 222 genes, DNA methylation change was not conditional on therapy response (all p > 0.05; Table 1), 223 with all Bayes factors larger than one and Bayes factors for DMR-1 above the threshold of three. 224 There were no statistically significant correlations between symptom changes and DNA methyla-225 tion changes (all p > 0.05; Table 2 and S2 Fig, lower row), with all Bayes factors larger than one. 226 Distributions of DNA methylation changes are shown in Fig 1, lower row by responder status. The 227 largest mean differences between time points was found for TSPAN9 (-2.78% \pm 9.78%), and the 228 smallest was -0.12% ± 3.35% for DMR-1. Mean DNA methylation levels pre- and post-intervention 229 averaged across the analyzed genomic regions are shown in S3 Fig. DNA methylation levels for 230 single CpGs are shown in S4 Table.

Equivalence tests showed that the effect sizes of *ADORA1*, *RPS6KA2*, and DMR-1 were all significantly smaller than 5% DNA methylation change in both the whole cohort and the responder cohort

(all $p_{corrected} < .001$). The effect of *TSPAN9* was only significantly different from 5% in the whole cohort on an uncorrected p = .043, which did not survive Bonferroni correction. Hence, although we cannot rule out that there is a true effect size as large as 5% DNA methylation change for the *TSPAN9* locus, we can conclude with relative certainty that true effect sizes of the WBGS nominated genes are smaller than 5%.

238

239 Validation of WGBS-nominated targets in the AN sample. In the AN cohort, DBS was per-240 formed for validation of targets that emerged from WGBS (methylation difference \geq 0.2) in all three 241 individuals as potentially responsive to weight gain in eight regions (four detected by both DMR-242 calling tools and four detected by camel: DMR-1 within Galactosidase Beta 1 Like (GLB1L), 243 intergenic DMR-3, DMR-7 within Family With Sequence Similarity 50 Member B (FAM50B), DMR-244 11 within Mesoderm Specific Transcript (MEST), DMR-13 within ER Lipid Raft Associated 2 245 (ERLIN2), DMR-16 within Exonuclease 3'-5' Domain Containing 3 (EXD3), DMR-22 within SNRPN 246 Upstream Reading Frame/ Small Nuclear Ribonucleoprotein Polypeptide N (SNURF/SNRPN) and 247 DMR-28 within Heat Shock Protein Family A (Hsp70) Member 12B (HSPA12B) (for DMR number-248 ing see S8 Table). All CpGs contained in the DMRs were included in the amplicons. Chromosomal 249 locations are shown in S2 Table.

Since for this cohort we had used a lower minimum methylation difference between groups (0.2), we first attempted technical confirmation using DBS in the same three individuals (pre- and posttreatment; same DNA preparation as for WGBS). As can be seen in S5 Fig, the methylation differences identified by WBGS could not be confirmed in any of these regions. Therefore, the four independent samples were not further analyzed.

255

256 **Discussion**

Epigenetic processes have been proposed as a potential mechanism mediating the link between exposure to trauma or adversity and mental health problems. Expectedly, there is great interest in the question whether psychological interventions translate into a modification of disorder-related epigenetic signatures. The first few studies addressing this question have found divergent patterns

of DNA methylation changes between patients who responded to therapy and those who did not. However, results of these pilot studies remain inconclusive, because differences in genetic background and changes in cell composition over time, which are the main confounders in epigenetic research, were not taken into account.

265 In our study, we avoided these confounders by using isogenic pre- and post-treatment samples 266 and a homogenous cell population (monocytes). Furthermore, we used DBS for targeted high 267 resolution methylation analysis. With this approach, we could not identify any evidence of interven-268 tion-associated changes in DNA methylation. We investigated four candidate genes that were pre-269 viously shown to be sensitive to variation in the social environment and/or seemed responsive to 270 intervention in a sample of female PTSD patients. The prime candidate for epigenetic research in 271 humans has been NR3C1, since DNA methylation of the promoter of alternative Exon 17 (1F in 272 humans) had been shown to vary as a function of maternal care in the rodent model [7]. We found 273 no change between pre- and post-intervention in PTSD patients and no differences between ther-274 apy responders and non-responders. We also investigated DNA methylation of SLC6A4, the most 275 widely studied candidate gene in psychiatry. One previous study found small increases in SLC6A4 276 methylation in therapy responders in one of four assessed CpG sites [17]. Here, we investigated 277 82 CpGs sites across the entire CpG island in the gene's promoter region and found no evidence 278 for change over time - neither overall nor when stratified by responders and non-responders. This 279 was also true for FKBP5, where we focused on 5 CpGs in intron 7, previously associated with 280 PTSD risk following early life adversity [31], and the OXTR gene, where we investigated 16 CpGs 281 in a putative enhancer region - characterized by H3K27 acetylation peaks - in intron 3 of the gene. 282 In sum, we did not observe intervention-associated changes in DNA methylation of commonly in-283 vestigated candidate genes when assessed in a homogenous cell population.

In small samples with limited statistical power, non-significant results do not provide evidence for the absence of meaningful effects. We thus further conducted equivalence tests to ascertain whether observed effect sizes are significantly smaller than a minimal effect size of interest. These revealed that DNA methylation changes of the four candidate genes were significantly below physiologically meaningful levels [32, 33]. Notably, this does not preclude that miniscule changes on

these genes might contribute to a meaningful epigenome-wide poly-epigenetic score, but such studies necessitate much larger samples and another theoretical perspective on the importance of single candidate genes than the studies whose effects we aimed to replicate.

292 Candidate gene studies can only provide a very limited view on potential dynamics of the 293 epigenome. True epigenome-wide studies covering the ~28 million CpG sites across the human 294 genome are still prohibitive in large cohorts because of the associated costs. Here, we used an 295 explorative strategy to identify genomic regions whose DNA methylation pattern might potentially 296 be responsive to intervention, by using WGBS in two PTSD and three AN patients before and after 297 therapy. We identified a small number of pre-to-post intervention DMRs (36 for PTSD and 38 for 298 AN). The validation of a subset of the identified PTSD DMRs in the remaining 58 patients could not 299 confirm the potential differential methylation patterns found by WGBS. In addition, AN DMRs iden-300 tified after reducing the stringency in DMR calling (by lowering to 0.2 the minimum methylation 301 difference allowed) could not be validated by DBS in the three samples subjected to WGBS.

302 It is remarkable that the change of physiological conditions for monocytes in AN due to adaption to 303 prolonged starvation is not associated with significant changes in DNA methylation pattern. This 304 suggests that cell type-specific methylation patterns are highly stable. This stability can probably 305 be attributed to stem or progenitor cells, because monocytes have a very short half-life in blood. 306 Pre- and post-treatment samples are not drawn from the same pool of monocytes, but are derived 307 from the same stem or progenitor cells. We previously showed differences in metabolic profiles in 308 patients with AN compared to controls and in patients with AN between acute stage of starvation 309 and after short term weight recovery. A substantial number of metabolite levels did not return to 310 normal after short term recovery [34]. It might be assumed that weight gain could exert an effect on 311 the methylome at a later time point.

It is important to reflect on the question whether it is plausible to expect changes of DNA methylation patterns in peripheral surrogate tissues that are associated with changes in thoughts, feelings or somatic alterations in a meaningful way. Three scenarios have been put forward previously: first, DNA methylation dynamics observed in blood or buccal epithelial cells reflect the processes occurring in neuronal cells [18]. However, as buccal epithelium or leukocytes do not have a biolog-

317 ically realistic link to cellular processes occurring in neurons, these transient and activity-318 dependent alterations of chromatin and the specific patterns of DNA methylation in neurons are 319 most likely not reflected in peripheral tissue.

320 The second scenario is that changes in peripheral DNA methylation patterns are brought about by 321 intervention-associated psychophysiological changes that parallel changes in thoughts and feel-322 ings. Such cross talk between the central nervous system and peripheral organs is arguably medi-323 ated through regulation of the autonomic nervous system and the hypothalamic-pituitary-adrenal 324 axis, activating the two main stress effectors noradrenaline and cortisol. These mediate their ef-325 fects by engaging cellular receptor systems, which ultimately regulate specific gene expression 326 responses. A testable model therefore suggests that changes in DNA methylation are brought 327 about by alterations of transcriptional activity associated with changes in upstream signaling of 328 stress mediators such as cortisol or noradrenalin [35].

The third scenario, which is in our opinion the most plausible explanation for many previous findings, is that changes in DNA methylation levels merely reflect changes in cell composition, which might be stochastic in nature, reflect differences in health status independent of disorder of interest, or reflect intervention-associated physiological changes. As such, change in the composition of the leukocyte pool might be a marker of therapy response [36].

334 The following limitations deserve a mention. The costs associated with WGBS limited the number 335 of patients to 2-3 for each cohort, so that only large pre-to-post differences could be reliably identi-336 fied. Power estimates show that we had 80% power to detect pre-to-post-treatment DNA methyla-337 tion differences of 30%. Furthermore, only one cell type was investigated. Monocytes have been 338 shown as the most sensitive subtype for social conditions and traumatic experiences, at least in 339 terms of transcriptional changes [26, 37-39]. However, any effects in other cell types (e.g., T cells, 340 B cells, NK cells, etc.), or changes in the relative prevalence of cells in the circulating leukocyte 341 pool are missed in this analysis.

In conclusion, our results provide no evidence in support of intervention-associated changes in
 DNA methylation in monocytes in PTSD or AN, and equivalence tests and Bayesian statistics pro vided evidence against even subtle DNA methylation changes associated with therapy outcome.

We argue that the previously reported changes in DNA methylation following therapy are most likely explained by changes in cell composition rather than by cellular reprogramming of DNA methylation. In itself, any shifts in cellular composition might reflect intervention-associated physiological changes and could therefore be used as biomarkers, but markers should not be confused with mechanisms.

350

351 Methods

352 Sample Characteristics, clinical judgement and treatment

PTSD cohort. We investigated sixty female in-patients of European descent seeking treatment for PTSD at the Department of Psychosomatic Medicine and Psychotherapy, LWL-University Hospital, Ruhr-University Bochum. The patients were between 20 and 60 years old (mean age: 40.0 ± 11.9 (SD) years), and the mean treatment duration was 6.5 ± 1.4 (SD) weeks. Inclusion criteria were PTSD diagnosis and female sex. The PTSD study was approved by the ethics committee of the Faculty of Psychology, Ruhr University Bochum (Nr. 155), and patients gave written informed consent (see S1 Table for more details).

All patients with PTSD were diagnosed with ICD-10 (F43.1; International Classification of Diseases, 10th revision, WHO, 1993) prior to in-patient admission via structured clinical interviews in the outpatient department of the hospital. Furthermore, symptoms of PTSD were recorded before and after in-patient treatment with the PCL-5.

Participants of the PTSD cohort received standard in-patient PTSD treatment. This involved one session each week of individual cognitive-behavioral therapy, three sessions of trauma group therapy, two sessions of trauma stabilization group therapy, one session of a "skills group", two sessions of kinesitherapy, two sessions of art therapy, physiotherapy, clinical rounds, and daily short sessions with a nurse. During individual therapy sessions patients received different trauma exposure methods. Overview of the study design is shown in Fig 3.

AN cohort. The second cohort comprised seven female adolescent patients with AN, receiving in patients treatment at the University Hospital Essen, University of Duisburg-Essen. The median age

372 was 16 (with first and third quartile: Q1, Q3; 15, 17) years, median height 162.5 (160.2, 167.7) cm, 373 median weight at admission 40.2 (37.6, 46.7) kg, median BMI at admission 15.2 (14.8, 16.1) kg/m². 374 Length of treatment was 94 (69, 99) days (see S1 Table 1 for sample characteristics). Inclusion 375 criteria for the AN group were a diagnosis of AN, female sex, German ancestry and age from 12 to 376 18 years. The AN study was approved by the ethics committee of the Faculty of Medicine, Univer-377 sity Hospital Essen (Nr. 06-3212 amendment of November 2016). Patients and their parents gave 378 written informed consent. Patients with AN were examined at the Department of Child and Adoles-379 cent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of 380 Duisburg-Essen according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition, 381 text revision (DSM-IV-TR) criteria [40]. AN diagnosis was confirmed via clinical examination and a 382 semi structured interview (Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS 383 [41]). Adolescent patients with AN participated in a multimodal multidisciplinary treatment program 384 based on dialectical behavioral therapy for adolescents that included weight restoration, individual 385 nutritional counseling, individual therapy (twice a week), skills-groups and individual skill training 386 (twice a week), family sessions (fortnightly), and a group psychoeducation program for parents 387 (monthly). During weight restoration, patients received nutritional counselling and meal support 388 training. Therapy goals were a weight gain of at least 500g per week and a minimum target weight 389 in the range of the 10-20th age-adjusted BMI percentile.

Patients with AN had a median BMI at admission of 15.2 (14.8, 16.1) kg/m² and median BMI at end of treatment was 17.5 (17.5, 17.8) kg/m². During the treatment period (i.e. hospital stay) of a median of 94 (69, 99) days, all seven patients gained considerable weight (median weight gain 5.8 (5.6, 6.7) kg; median BMI gain 2.2 (2.0, 2.4) kg/m²).

394

395 Sample preparation and targeted deep bisulfite sequencing

Nine ml blood was drawn in the morning between 7-9 am (S-Monovette 9 ml K3E, Sarstedt). Monocytes were immunomagnetically purified from whole blood with the MACS System (Miltenyi Biotec, Bergisch Gladbach, Germany), shock frozen and stored at -80°C. DNA was isolated with the AllPrep RNA/DNA Mini Kit (Qiagen, Hilden, Germany). For DBS, DNA was bisulfite-modified

- 400 with the EZ DNA Methylation Gold Kit (Zymo Research, Orange, CA, USA) and processed as de-
- 401 scribed elsewhere [42, 43] using primers as indicated in S2 Table.
- 402

403 Whole-genome bisulfite sequencing

For PTSD samples, WGBS libraries were prepared as previously described [44]. For the AN samples, 5 µg DNA at 50 ng/µl in water was used for library preparation and NGS sequencing on a
HiSeq X platform (DKFZ Genomics & Proteomics Core Facility (GPCF) with 1 sample per lane.
Read data from both datasets were processed as described previously [45, 46]. As a reference
genome, we used hg19. For calling DMRs, we used camel [30] and metilene [29].

409

410 **Statistical Analyses**

Repeated measures analyses of variance (ANOVA) were performed to assess changes in DNA methylation. Therapy response was included as an additional between-subject factor to check for therapy outcome-dependent changes in DNA methylation. Moreover, Pearson correlations were computed between percent DNA methylation change and PCL-5 symptom change to test a continuous measure of therapy response. In addition to changes over time, linear regression analysis was performed with pre-treatment mean DNA methylation of DBS targets and severity of baseline PTSD symptoms.

418 Our sample size of N = 60 was based on the average sample size of previous studies in therapy-419 contingent DNA methylation changes in mental disorders (M = 69, range = 16-115). Due to the 420 heterogeneity of reported effect sizes, statistical tests, designs, and populations, a principled effect 421 size estimation based on previous studies was not suitable in our case. We thus performed a sen-422 sitivity analysis with the software *qpower* [47], which showed acceptable statistical power ($\beta = .80$) 423 to detect small changes from pre- to post-treatment at $\eta^2 = .03$, assuming a correlation between 424 pre- and post-intervention methylation of r = .50. For comparisons between responders and non-425 responders or correlations between symptom change and methylation change, moderate effect 426 sizes at $\eta^2 = .09$ can be detected with sufficient statistical power, which is still in the range of previ-427 ously reported effect sizes [13].

428	Generally, non-significant results do not provide evidence for the null hypothesis (i.e. absence of
429	effect), especially when the statistical power is limited. Therefore, p-values were supplemented
430	with Bayes factors to quantify the evidence for the null hypothesis using the BayesFactor package
431	(v0.9.12-4.2) in R (3.6.1) and non-informative default priors [48, 49].
432	Complementary to the Bayesian approach, we conducted equivalence tests to assess whether

effect sizes in DNA methylation change are significantly smaller than the smallest biologically meaningful effect size. It has been argued that DNA methylation below 5% should be interpreted with extreme caution [32, 33]. We used the two one-tailed t-test procedure [50] to check whether

- 436 empirical effect sizes for methylation change are smaller than 5% or even a more conservative 1%.
- 437 For a detailed account of statistical methods please see S2 Methods.
- 438

439 **Acknowledgement**

- 440 We thank the Cologne Center for Genomics (CCG) and the DKFZ Genomics & Proteomics Core
- 441 Facility (GPCF) for performing WGBS.
- 442

444	References
-----	------------

445	1.	Szyf M. The early life social environment and DNA methylation: DNA methylation mediating the
446	long-te	erm impact of social environments early in life. <i>Epigenetics</i> 2011; 6 (8): 971-978.
447		
448	2.	Hubel C, Marzi SJ, Breen G, Bulik CM. Epigenetics in eating disorders: a systematic review. Mol
449	Psychi	atry 2019; 24 (6): 901-915.
450		
451	3.	Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet 2016; 17(8):
452	487-50	00.
453		
454	4.	Godfrey KM, Costello PM, Lillycrop KA. The developmental environment, epigenetic biomarkers
455	and lor	ng-term health. J Dev Orig Health Dis 2015; 6(5): 399-406.
456		
457	5.	McGowan PO, Szyf M. The epigenetics of social adversity in early life: implications for mental
458	health	outcomes. <i>Neurobiol Dis</i> 2010; 39 (1): 66-72.
459		
460	6.	Tobi EW, Slieker RC, Luijk R, Dekkers KF, Stein AD, Xu KM et al. DNA methylation as a media-
461	tor of t	he association between prenatal adversity and risk factors for metabolic disease in adulthood. Sci Adv
462	2018; 4	4 (1): eaao4364.
463		
464	7.	Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR et al. Epigenetic pro-
465	gramm	ing by maternal behavior. Nat Neurosci 2004; 7(8): 847-854.
466		
467	8.	Dekkers KF, van Iterson M, Slieker RC, Moed MH, Bonder MJ, van Galen M et al. Blood lipids
468	influer	ce DNA methylation in circulating cells. Genome Biol 2016; 17(1): 138.
469		
470	9.	Emeny RT, Baumert J, Zannas AS, Kunze S, Wahl S, Iurato S et al. Anxiety Associated Increased
471	CpG M	Iethylation in the Promoter of Asb1: A Translational Approach Evidenced by Epidemiological and
472	Clinica	al Studies and a Murine Model. Neuropsychopharmacology 2018; 43(2): 342-353.

473		
474	10.	Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR et al. Epigenetic Signa-
475	tures o	of Cigarette Smoking. Circ Cardiovasc Genet 2016; 9(5): 436-447.
476		
477	11.	Saunderson EA, Spiers H, Mifsud KR, Gutierrez-Mecinas M, Trollope AF, Shaikh A et al. Stress-
478	induce	d gene expression and behavior are controlled by DNA methylation and methyl donor availability in
479	the der	ntate gyrus. Proc Natl Acad Sci U S A 2016; 113(17): 4830-4835.
480		
481	12.	Wong CC, Caspi A, Williams B, Craig IW, Houts R, Ambler A et al. A longitudinal study of epige-
482	netic v	variation in twins. <i>Epigenetics</i> 2010; 5 (6): 516-526.
483		
484	13.	Kumsta R. The role of epigenetics for understanding mental health difficulties and its implications
485	for psy	chotherapy research. Psychol Psychother 2019; 92(2): 190-207.
486		
487	14.	Roberts S, Keers R, Lester KJ, Coleman JR, Breen G, Arendt K et al. Hpa Axis Related Genes and
488	Respo	nse to Psychological Therapies: Genetics and Epigenetics. Depress Anxiety 2015; 32(12): 861-870.
489		
490	15.	Roberts S, Keers R, Breen G, Coleman JRI, Johren P, Kepa A et al. DNA methylation of FKBP5
491	and rea	sponse to exposure-based psychological therapy. Am J Med Genet B Neuropsychiatr Genet 2019;
492	180 (2)	: 150-158.
493		
494	16.	Yehuda R, Daskalakis NP, Desarnaud F, Makotkine I, Lehrner AL, Koch E et al. Epigenetic Bi-
495	omark	ers as Predictors and Correlates of Symptom Improvement Following Psychotherapy in Combat Vet-
496	erans v	with PTSD. Front Psychiatry 2013; 4: 118.
497		
498	17.	Roberts S, Lester KJ, Hudson JL, Rapee RM, Creswell C, Cooper PJ et al. Serotonin transporter
499	[correc	cted] methylation and response to cognitive behaviour therapy in children with anxiety disorders.
500	Transl	<i>Psychiatry</i> 2014; 4: e444.
501		

502	18.	Ziegler C, Richter J, Mahr M, Gajewska A, Schiele MA, Gehrmann A et al. MAOA gene
503	hypom	ethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy. Transl Psy-
504	chiatry	2016; 6: e773.
505		
506	19.	Perroud N, Salzmann A, Prada P, Nicastro R, Hoeppli ME, Furrer S et al. Response to psychothera-
507	py in b	orderline personality disorder and methylation status of the BDNF gene. Transl Psychiatry 2013; 3:
508	e207.	
509		
510	20.	Vinkers CH, Geuze E, van Rooij SJH, Kennis M, Schur RR, Nispeling DM et al. Successful treat-
511	ment of	f post-traumatic stress disorder reverses DNA methylation marks. Mol Psychiatry 2019.
512		
513	21.	Steiger H, Booij L, Kahan, McGregor K, Thaler L, Fletcher E et al. A longitudinal, epigenome-wide
514	study o	f DNA methylation in anorexia nervosa: results in actively ill, partially weight-restored, long-term
515	remitte	d and non-eating-disordered women. J Psychiatry Neurosci 2019; 44(3): 205-213.
516		
517	22.	Farre P, Jones MJ, Meaney MJ, Emberly E, Turecki G, Kobor MS. Concordant and discordant DNA
518	methyla	ation signatures of aging in human blood and brain. Epigenetics Chromatin 2015; 8: 19.
519		
520	23.	Nowak J, Borkowska B, Pawlowski B. Leukocyte changes across menstruation, ovulation, and mid-
521	luteal p	hase and association with sex hormone variation. Am J Hum Biol 2016; 28(5): 721-728.
522		
523	24.	Cole SW. Elevating the perspective on human stress genomics. Psychoneuroendocrinology 2010;
524	35 (7): 9	955-962.
525		
526	25.	Jones MJ, Moore SR, Kobor MS. Principles and Challenges of Applying Epigenetic Epidemiology
527	to Psyc	hology. Annu Rev Psychol 2018; 69: 459-485.
528		

529	26.	Cole SW, Hawkley LC, Arevalo JM, Cacioppo JT. Transcript origin analysis identifies antigen-					
530	presenting cells as primary targets of socially regulated gene expression in leukocytes. Proc Natl Acad Sci U						
531	S A 20	011; 108 (7): 3080-3085.					
532							
533	27.	Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for					
534	DSM	-5 (PCL-5). Scale available from the National Center for PTSD at www.ptsdvagov 2013.					
535							
536	28.	Ziller MJ, Hansen KD, Meissner A, Aryee MJ. Coverage recommendations for methylation analysis					
537	by wh	nole-genome bisulfite sequencing. Nat Methods 2015; 12(3): 230-232, 231 p following 232.					
538							
539	29.	Juhling F, Kretzmer H, Bernhart SH, Otto C, Stadler PF, Hoffmann S. metilene: fast and sensitive					
540	callin	g of differentially methylated regions from bisulfite sequencing data. Genome Res 2016; 26(2): 256-					
541	262.						
542							
543	30.	Schröder C. Bioinformatics from genetic variants to methylation. 2018.					
544							
545	31.	Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM et al. Allele-specific					
546	FKBF	P5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 2013; 16(1): 33-41.					
547							
548	32.	Michels KB, Binder AM, Dedeurwaerder S, Epstein CB, Greally JM, Gut I et al. Recommendations					
549	for the	e design and analysis of epigenome-wide association studies. <i>Nat Methods</i> 2013; 10 (10): 949-955.					
550							
551	33.	Leenen FA, Muller CP, Turner JD. DNA methylation: conducting the orchestra from exposure to					
552	pheno	otype? Clin Epigenetics 2016; 8: 92.					
553							
554	34.	Föcker M, Timmesfeld N, Scherag S, Knoll N, Singmann P, Wang-Sattler R et al. Comparison of					
555	metab	polic profiles of acutely ill and short-term weight recovered patients with anorexia nervosa reveals al-					
556	teratio	ons of 33 out of 163 metabolites. J Psychiatr Res 2012; 46(12): 1600-1609.					
557							

558	35.	Zannas AS, Chrousos GP. Epigenetic programming by stress and glucocorticoids along the human						
559	lifespan. Mol Psychiatry 2017; 22(5): 640-646.							
560								
561	36.	Holbrook JD, Huang RC, Barton SJ, Saffery R, Lillycrop KA. Is cellular heterogeneity merely a						
562	confou	nder to be removed from epigenome-wide association studies? <i>Epigenomics</i> 2017; 9 (8): 1143-1150.						
563								
564	37.	Cole SW, Conti G, Arevalo JM, Ruggiero AM, Heckman JJ, Suomi SJ. Transcriptional modulation						
565	of the c	leveloping immune system by early life social adversity. Proc Natl Acad Sci U S A 2012; 109(50):						
566	20578-	20583.						
567								
568	38.	O'Donovan A, Sun B, Cole S, Rempel H, Lenoci M, Pulliam L et al. Transcriptional control of mon-						
569	ocyte g	ene expression in post-traumatic stress disorder. Disease markers 2011; 30(2-3): 123-132.						
570								
571	39.	Powell ND, Sloan EK, Bailey MT, Arevalo JM, Miller GE, Chen E et al. Social stress up-regulates						
572	inflamı	natory gene expression in the leukocyte transcriptome via beta-adrenergic induction of myelopoiesis.						
573	Proc N	atl Acad Sci U S A 2013; 110 (41): 16574-16579.						
574								
575	40.	(2000). APA. Diagnostic and statistical manual of mental disorders (4th ed., Text Revision): Wash-						
576	ington,	2000.						
577								
578	41.	Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P et al. Schedule for Affective Disorders						
579	and Scl	nizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability						
580	and val	idity data. J Am Acad Child Adolesc Psychiatry 1997; 36(7): 980-988.						
581								
582	42.	Rahmann S, Beygo J, Kanber D, Martin M, Horsthemke B, Buiting K. Amplikyzer: Automated						
583	methyl	ation analysis of amplicons from bisulfite flowgram sequencing. PeerJ Preprints 2013.						
584								

585	43.	Moser DA, Müller S, Hummel EM, Limberg AS, Dieckmann L, Frach L et al. Targeted bisulfite					
586	sequencing: A novel tool for the assessment of DNA methylation with high sensitivity and increased cover-						
587	age. Psychoneuroendocrinology 2020.						
588							
589	44.	Leitão E, Di Persio S, Laurentino S, Wöste M, Dugas M, Kliesch S et al. The sperm epigenome does					
590	not disj	play recurrent epimutations in patients with severely impaired spermatogenesis. Clinical Epigenetics					
591	2020; 1	12 (1).					
592							
593	45.	Rademacher K, Schroder C, Kanber D, Klein-Hitpass L, Wallner S, Zeschnigk M et al. Evolutionary					
594	origin a	and methylation status of human intronic CpG islands that are not present in mouse. Genome Biol					
595	Evol 20	014; 6 (7): 1579-1588.					
596							
597	46.	Wallner S, Schroder C, Leitao E, Berulava T, Haak C, Beisser D et al. Epigenetic dynamics of mon-					
598	ocyte-t	o-macrophage differentiation. Epigenetics Chromatin 2016; 9: 33.					
599							
600	47.	Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program					
601	for the	social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39(2): 175-191.					
602							
603	48.	Rouder JN, Morey RD, Speckman PL, Province JM. Default Bayes factors for ANOVA designs.					
604	Journa	l of Mathematical Psychology 2012; 56(5): 356–374.					
605							
606	49.	Jarosz AF, Wiley J. What Are the Odds? A Practical Guide to Computing and Reporting Bayes Fac-					
607	tors. Th	ne Journal of Problem Solving 2014; 7(1): 1037–1040.					
608							
609	50.	Lakens D. Equivalence Tests: A Practical Primer for t Tests, Correlations, and Meta-Analyses. Soc					
610	Psycho	l Personal Sci 2017; 8(4): 355-362.					

611 Supporting Information

- 612
- 613 S1 Methods. Cell homogeneity.
- 614 **S2 Methods. Statistical analysis.**
- 615 S1 Table. Sample Characteristics.
- 616 S2 Table. Primer Sequences.
- 617 S3 Table. Linear regression with pre-treatment mean DNA methylation and severity
- of baseline PTSD symptoms.
- 619 **S4** Table. Mean DNA methylation levels at single CpG sites.
- 620 **S5 Table. WGBS descriptive information.**
- 621 S6 Table. DMRs in the PTSD cohort identified with camel.
- 622 S7 Table. DMRs in the PTSD cohort identified with metilene.
- 623 **S8** Table. DMRs in the AN cohort identified with camel.
- 624 **S9** Table. DMRs in the AN cohort identified with metilene.
- 625 S1 Fig. Chromosomal location of analyzed regions of the PTSD cohort.
- 626 S2 Fig. Correlations between symptom change and DNA methylation change in the
- 627 **PTSD cohort.**
- 628 S3 Fig. Mean DNA Methylation of the PTSD cohort.
- 629 **S4 Fig. Principal component analysis.**
- 630 **S5 Fig. DNA methylation differences of the AN cohort.**
- 631
- 632

633 Tables

634

Table 1. Effect of intervention and the effect of intervention by responder status

interaction on DNA methylation in the PTSD cohort

		Intervention			Intervention x responder			
	F	p	$\eta_{\rm G}^2$	BF ₀₁	F	p	$\eta_{\rm G}^2$	BF_{01}
A) Candidate Gene	es							
NR3C1	1.72	.196	.01	3.05	1.94	.170	.01	1.58
SLC6A4	1.25	.268	.00	2.69	0.01	.926	.00	3.65
OXTR	2.77	.102	.01	1.85	0.58	.449	.00	2.78
FKBP5	0.47	.494	.00	4.12	0.08	.784	.00	3.69
B) New Targets from WGBS								
ADORA1	3.52	.065	.01	0.64	0.61	.439	.00	2.75
TSPAN9	3.22	.078	.01	0.74	0.84	.363	.00	2.43
RPS6KA2	0.15	.701	.00	5.19	1.06	.308	.00	2.63
DMR-1	0.07	.790	.00	5.06	0.22	.640	.00	3.34

Note. Results from a mixed model analysis of variance. $\eta_{\tilde{6}}^2$ = generalized eta squared. BF_{01} = Bayes factor quantifying the evidence for the null hypothesis against the alternative hypothesis. Bayes factors above 3 are interpreted as substantial evidence for the null hypothesis and shown in boldface. Numerator df = 1 for all tests. Denominator df for NR3C1= 51 and for *RPS6KA2* = 54 due to missing values. For all other genes denominator df = 55.

636

Table 2. Correlations between change in DNA methylation and change in symptom scores (PTSD cohort).

Gene	r	95% CI	p	BF ₀₁
A) Candidate Genes				
NR3C1	17	[42, .11]	.235	1.70
SLC6A4	02	[28, .24]	.874	3.30
OXTR	.11	[16, .36]	.425	2.50
FKBP5	04	[30, .22]	.778	3.22
B) New Targets from WGBS				
ADORA1	19	[43, .07]	.155	1.32
TSPAN9	.16	[11, .40]	.242	1.78
RPS6KA2	12	[37, .14]	.365	2.28
DMR-1	10	[35, .17]	.473	2.64

Note. r = pearson correlation. $BF_{01} =$ Bayes factor of For *NR3C1*, n = 53. For *RPS6KA2*, n = 56. For all remaining genes, n = 57. $BF_{01} =$ Bayes factor quantifying the evidence for the null hypothesis against the alternative hypothesis. Bayes factors above 3 are interpreted as substantial evidence for the null hypothesis and shown in boldface.

638 Figure legends

- 639
- 640 Fig 1. Density plots for the distribution of DNA methylation change (post minus pre-
- 641 treatment) by therapy response and gene.
- 642
- 643 Fig 2. Cluster analysis of 1,000 most variable CpGs. A) The PTSD monocyte methylomes were
- obtained from two individuals (47 and 43), pre- (.1) and post-intervention (.2). B) The AN mono-
- 645 cyte methylomes were obtained pre- and post-treatment from three individuals (AN1, AN2 and
- AN3). CpG SNPs were excluded from the analysis. The difference between individuals is much
- greater than between pre- and post-intervention.
- 648
- 649 **Fig 3. Overview of the study design.**



Change in methylation (%)





